Collegium Pharmaceutical, Inc (COLL): Revenue
$780.57M
Year ended 2025-12-31
$808.21M
Trailing 12 months to 2026-06-30
+18.9%
3-year compound annual growth
+20.3%
5-year compound annual growth
| Period ended | Revenue | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $780.57M | +23.6% | 2026-02-26, From 2025-01-01 |
| 2024-12-31 | $631.45M | +11.4% | 2026-02-26, From 2024-01-01 |
| 2023-12-31 | $566.77M | +22.2% | 2026-02-26, From 2023-01-01 |
| 2022-12-31 | $463.93M | +67.6% | 2025-02-27, From 2022-01-01 |
| 2021-12-31 | $276.87M | -10.7% | 2024-02-22, From 2021-01-01 |
| 2020-12-31 | $310.02M | +4.5% | 2023-02-23, From 2020-01-01 |
| 2019-12-31 | $296.70M | +5.8% | 2022-02-24, From 2019-01-01 |
| 2018-12-31 | $280.41M | +884.7% | 2021-02-25, From 2018-01-01 |
| 2017-12-31 | $28.48M | n/m | 2020-02-27, From 2017-01-01 |
| 2016-12-31 | $1.71M | n/a | 2019-02-27, From 2016-01-01 |
Revenue at similar companies
| Company | Year ended | Revenue | Change YoY |
|---|---|---|---|
| Collegium Pharmaceutical, Inc (COLL) | 2025-12-31 | $780.57M | +23.6% |
| Corcept Therapeutics Inc (CORT) | 2025-12-31 | $761.41M | +12.8% |
| Emergent BioSolutions Inc. (EBS) | 2025-12-31 | $742.90M | -28.8% |
| Arrowhead Pharmaceuticals, Inc. (ARWR) | 2025-09-30 | $829.45M | n/m |
| Pacira BioSciences, Inc. (PCRX) | 2025-12-31 | $726.41M | +3.6% |
| Amphastar Pharmaceuticals, Inc. (AMPH) | 2025-12-31 | $719.89M | -1.7% |
| Supernus Pharmaceuticals, Inc. (SUPN) | 2025-12-31 | $718.95M | +8.6% |
| Harmony Biosciences Holdings, Inc. (HRMY) | 2025-12-31 | $868.45M | +21.5% |
| ANI Pharmaceuticals Inc (ANIP) | 2025-12-31 | $883.37M | +43.8% |
Compare COLL, CORT, EBS, ARWR side by side · Screen every company in Pharmaceutical Preparations ↗